West Cancer Center

BREAST: PERI-OPERATIVE: TNBC: SCARLET

Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study

Title

SWOG S2212 SCARLET Breast Cancer perioperative TNBC

Study Title

Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study

Site Link

NCT05929768

Malignancy

Breast, IBC

Stage

Stage 3

Disease Setting

Adjuvant/Post-surgical

Line Of Therapy

Peri-operative

Investigational Agent

Carboplatin, Paclitaxel, Pembrolizumab

Drug Class

Chemotherapy, PD-1 inhibitor

Greg Vidal, MD, PhD

Sponsor

SWOG

Phase

Phase 3

Status

Open to Enrollment

Key Eligibility Criteria

Key Eligibility Criteria Details

ER-, PR-, HER2- TNBC
Clinical stage either
- T2-T4, N0, M0 or
- T1-T3, N1-2, M0
- No T4/N+, any N3, or inflammatory breast cancer
No prior systemic therapy for curative intent
No previous ipsilateral surgery for current breast surgery
ECOG PS 0-

Objective

Primary
- Breast cancer event free survival
Secondary
- Path CR
- Residual cancer burden
- Distant relapse-free survival
- OS
- Distant relapse-free interval
- RFS
- Safety
- QOL

Assessment Frequency

Assessment Frequency 2

Assessment Frequency Link

Path

ER negative, PR negative, HER2 negative, TNBC

Dosing Frequency

Control Agents

Study Protocol

Randomized

Yes